Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Agreement provides potential opportunity for oncology patients to have access to improved therapies

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) — Elektrofi, Inc., a biopharmaceutical formulation technology company focused on transforming the delivery of biologic therapies through strategic partnerships, announced today that it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company. This collaboration will initially focus on developing an at home self-administered subcutaneous version of a lead oncology asset. The agreement was facilitated by Johnson & Johnson Innovation.

“Our strategic partnership integrates Elektrofi’s formulation expertise with Janssen’s proven oncology development and commercialization strengths,” said Chase Coffman, Ph.D., Chief Executive Officer of Elektrofi. “By shifting the setting for certain Janssen oncology therapeutics into the home, and enabling the convenience of self-administration, this collaboration aims to improve access to groundbreaking treatments for patients that need it most. These next generation therapies not only have the potential to enhance patients’ lives, but also transform their overall treatment experience.”

Under the terms of the agreement, Elektrofi will receive an upfront payment of $18 million in exchange for Janssen receiving the exclusive right to a lead Janssen oncology target and up to four additional targets. Elektrofi will be eligible to receive future milestones surpassing $155 million per target, subject to achieving developmental, regulatory, and sales-based milestones, as well as a tiered upper mid-single digit royalty on global net sales for commercialized products. Janssen will be responsible for each product’s clinical development and commercialization.

The strategic partnership with Janssen further expands the use of Elektrofi’s innovative formulation technology platform. Through its collaborations with leading pharmaceutical companies, Elektrofi has the potential to develop up to 12 unique products with its partners.

“We are united in our partners’ success, and we are as driven as they are to bring their biologic therapies to patients in new ways by enabling them to be subcutaneously delivered, at-home or anywhere a patient desires,” said Coffman.

About Elektrofi
Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough ultra-high concentration microparticle technology platform resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally.

Formulating the Future of Biologics™ www.Elektrofi.com

Elektrofi Media Inquiries: media@elektrofi.com

Staff

Recent Posts

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…

1 hour ago

Rocketseed launches essential email signature guide for healthcare organizations

New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…

1 hour ago

Hospital PMI® at 52%; May 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…

1 hour ago

Infisical Secures $16M Series A to Redefine Enterprise Secrets, Identity, and Access Management

Open-source leader democratizes enterprise-grade secrets management for fastest-growing startups, Fortune 500 enterprises, and nation-states. SAN…

1 hour ago

Choctaw Nation and Healthy Together Launch Streamlined Summer EBT Program in Just Six Weeks

MIAMI, June 6, 2025 /PRNewswire/ -- Healthy Together, a leading provider of health and human…

1 hour ago

Improved Pharma Expands Footprint at Kurz Purdue Technology Center, Now Occupying Over 5,500 Square Feet

Fifth expansion since 2020 reflects growing demand for advanced pharmaceutical analysis and development services. WEST…

1 hour ago